PYPD
PolyPid·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PYPD
Polypid Ltd.
A biopharmaceutical company developing and commercializing extended-release, locally administered therapies
18 Hasivim Street, Petach Tikva 4959376, Israel
--
PolyPid Ltd., incorporated under the laws of Israel, commenced operations on February 28, 2008. The Company is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, topically administered and sustained-release therapies using proprietary PLEX technology. The company's product candidates are designed to address diseases with high unmet medical need by pairing PLEX technology with FDA-approved drugs or innovative drug candidates to achieve new therapeutic effects.
Earnings Call
Q1/2025
Estimate EPS-0.82
Actual EPS-0.7
Estimate Revenue--
Actual Revenue0
PolyPid's Q1 2025: Key Contradictions in Pricing, FDA Readiness, and Clinical Protocols
May 20,2025 09:21
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.55
Actual EPS-0.78
Estimate Revenue--
Actual Revenue0
PolyPid's Q2 2025 Earnings Call: Key Contradictions on CMC Readiness, GLP-1 Program, and Partnership Dynamics
Aug 13,2025 05:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PYPD has released its 2025 Q3 earnings. EPS was reported at -0.37, versus the expected -0.52, beating expectations. The chart below visualizes how PYPD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
